Published in Curr Opin Gastroenterol on January 01, 2007
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2012) 0.91
Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics (2007) 0.90
Four human thiopurine s-methyltransferase alleles severely affect protein structure and dynamics. J Mol Biol (2008) 0.89
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13
Inheritance and drug response. N Engl J Med (2003) 5.78
Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet (2001) 5.00
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol (1994) 2.94
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Pharmacogenomics: bench to bedside. Nat Rev Drug Discov (2004) 1.63
Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol (1996) 1.53
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 1.50
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet (1999) 1.48
Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol (2005) 1.36
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A (1995) 1.36
The genetic basis of variability in drug responses. Nat Rev Drug Discov (2002) 1.34
Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet (1998) 1.31
Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics (1998) 1.30
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood (1995) 1.29
A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol (2005) 1.27
Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics (1992) 1.26
Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A (1997) 1.23
Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res (2001) 1.22
Trimethylaminuria and a human FMO3 mutation database. Hum Mutat (2003) 1.20
Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit (2004) 1.19
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther (1995) 1.17
Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther (1982) 1.17
Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model. Mayo Clin Proc (2004) 1.14
Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia (1998) 1.14
Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol (1995) 1.13
Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab Dispos (2002) 1.12
Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet (1997) 1.10
Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res (1999) 1.10
Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol (1993) 1.08
Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system. Biochem Biophys Res Commun (2003) 1.08
The thiopurines: an update. Invest New Drugs (2005) 1.05
Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J (2005) 1.03
Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology (2004) 1.01
Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut (1996) 1.01
The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today (2004) 0.98
Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J Inherit Metab Dis (1997) 0.95
Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit (2005) 0.90
Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem Pharmacol (2000) 0.90
Azathioprine: current status and future considerations. Int J Dermatol (2003) 0.89
Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2005) 0.87
Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res (2004) 0.85
The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer (1998) 0.84
Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest (2006) 0.83
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer (1998) 0.82
5-fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol (2003) 0.81
Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J (2001) 0.80
The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development (2002) 5.09
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene (2004) 2.96
Krüppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res (2005) 2.73
The diverse functions of Krüppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays (2007) 2.40
Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology (2008) 2.31
Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem (2002) 2.19
Transcriptional profiling of Krüppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J Mol Biol (2003) 2.11
Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene (2003) 2.11
Novel cross talk of Kruppel-like factor 4 and beta-catenin regulates normal intestinal homeostasis and tumor repression. Mol Cell Biol (2006) 1.96
Requirement of Krüppel-like factor 4 in preventing entry into mitosis following DNA damage. J Biol Chem (2003) 1.76
Krüppel-like factor 6 regulates mitochondrial function in the kidney. J Clin Invest (2015) 1.72
Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res (2007) 1.71
Krüppel-like factor 5 mediates the transforming activity of oncogenic H-Ras. Oncogene (2004) 1.70
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Opposing effects of Krüppel-like factor 4 (gut-enriched Krüppel-like factor) and Krüppel-like factor 5 (intestinal-enriched Krüppel-like factor) on the promoter of the Krüppel-like factor 4 gene. Nucleic Acids Res (2002) 1.64
Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology (2012) 1.64
Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. Gastroenterology (2007) 1.58
The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology (2009) 1.56
Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res (2007) 1.47
Notch inhibits expression of the Krüppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol Cancer Res (2008) 1.46
Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res (2010) 1.44
Krüppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage. Oncogene (2005) 1.40
Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genet Med (2011) 1.37
All-trans retinoic acid inhibits proliferation of intestinal epithelial cells by inhibiting expression of the gene encoding Kruppel-like factor 5. FEBS Lett (2004) 1.35
KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood (2006) 1.33
Krüppel-like factor 5 promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenic Ras-mediated transformation. FEBS Lett (2005) 1.31
Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res (2008) 1.30
Haploinsufficiency of Krüppel-like factor 5 rescues the tumor-initiating effect of the Apc(Min) mutation in the intestine. Cancer Res (2009) 1.29
Enterocyte differentiation marker intestinal alkaline phosphatase is a target gene of the gut-enriched Kruppel-like factor. Am J Physiol Gastrointest Liver Physiol (2003) 1.29
Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5. J Biol Chem (2007) 1.29
Kruppel-like factor 5 is an important mediator for lipopolysaccharide-induced proinflammatory response in intestinal epithelial cells. Nucleic Acids Res (2006) 1.28
Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells. J Biol Chem (2004) 1.22
p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res (2007) 1.20
SUMOylation regulates nuclear localization of Krüppel-like factor 5. J Biol Chem (2008) 1.18
The role of Krüppel-like factors in the reprogramming of somatic cells to induced pluripotent stem cells. Histol Histopathol (2009) 1.15
Altered intestinal epithelial homeostasis in mice with intestine-specific deletion of the Krüppel-like factor 4 gene. Dev Biol (2010) 1.14
Krüppel-like factor 5 mediates transmissible murine colonic hyperplasia caused by Citrobacter rodentium infection. Gastroenterology (2008) 1.11
Krüppel-like factor 5 is important for maintenance of crypt architecture and barrier function in mouse intestine. Gastroenterology (2011) 1.10
KLF4 is a FOXO target gene that suppresses B cell proliferation. Int Immunol (2008) 1.08
Expression of the tumor suppressor Krüppel-like factor 4 as a prognostic predictor for colon cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.06
The Role of Inflammation in the Pathogenesis of Colorectal Cancer. Curr Colorectal Cancer Rep (2009) 1.04
Krüppel-like factor 5 protects against dextran sulfate sodium-induced colonic injury in mice by promoting epithelial repair. Gastroenterology (2010) 1.03
Krüppel-like factor 5 is a crucial mediator of intestinal tumorigenesis in mice harboring combined ApcMin and KRASV12 mutations. Mol Cancer (2010) 1.03
Kruppel-like factors regulate the Lama1 gene encoding the laminin alpha1 chain. J Biol Chem (2003) 1.02
The Pathobiology of Krüppel-like Factors in Colorectal Cancer. Curr Colorectal Cancer Rep (2008) 1.02
Protein inhibitor of activated STAT1 interacts with and up-regulates activities of the pro-proliferative transcription factor Krüppel-like factor 5. J Biol Chem (2006) 1.02
Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology (2004) 1.01
Transcriptional profiling of the cell cycle checkpoint gene krüppel-like factor 4 reveals a global inhibitory function in macromolecular biosynthesis. Gene Expr (2006) 0.98
Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem (2012) 0.98
Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim Biophys Acta (2007) 0.97
The challenges facing GI investigators today and what (more) the GI societies can do to help. Gastroenterology (2007) 0.97
Regulation of hypoxia-inducible factor 1α (HIF-1α) by lysophosphatidic acid is dependent on interplay between p53 and Krüppel-like factor 5. J Biol Chem (2013) 0.97
Krüppel-like factor 4 regulates genetic stability in mouse embryonic fibroblasts. Mol Cancer (2013) 0.96
Identification of small-molecule inhibitors of the colorectal cancer oncogene Krüppel-like factor 5 expression by ultrahigh-throughput screening. Mol Cancer Ther (2011) 0.94
Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening. Mol Cancer Ther (2009) 0.93
Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus. Contemp Clin Trials (2008) 0.92
A small ubiquitin-related modifier-interacting motif functions as the transcriptional activation domain of Krüppel-like factor 4. J Biol Chem (2010) 0.92
The E3 ubiquitin ligase SMAD ubiquitination regulatory factor 2 negatively regulates Krüppel-like factor 5 protein. J Biol Chem (2011) 0.91
Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics (2007) 0.90
Helicobacter pylori promotes the expression of Krüppel-like factor 5, a mediator of carcinogenesis, in vitro and in vivo. PLoS One (2013) 0.90
Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice. Gastroenterology (2011) 0.90
Molecular Genetics of Colorectal Cancer: An Overview. Curr Colorectal Cancer Rep (2006) 0.87
Genetics of colorectal cancer. MedGenMed (2004) 0.87
Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2005) 0.87
Genetic deletion of Klf4 in the mouse intestinal epithelium ameliorates dextran sodium sulfate-induced colitis by modulating the NF-κB pathway inflammatory response. Inflamm Bowel Dis (2014) 0.86
Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res (2004) 0.85
HIV/AIDS and Colorectal Cancer: A Review in the Era of Antiretrovirals. Gastroenterol Hepatol (N Y) (2008) 0.85
Genetic and Chemical Models of Colorectal Cancer in Mice. Curr Colorectal Cancer Rep (2010) 0.85
A colon cancer-derived mutant of Krüppel-like factor 5 (KLF5) is resistant to degradation by glycogen synthase kinase 3β (GSK3β) and the E3 ubiquitin ligase F-box and WD repeat domain-containing 7α (FBW7α). J Biol Chem (2014) 0.84
Mitotic Origins of Chromosomal Instability in Colorectal Cancer. Curr Colorectal Cancer Rep (2007) 0.84
Histone lysine-specific demethylase 1 (LSD1) protein is involved in Sal-like protein 4 (SALL4)-mediated transcriptional repression in hematopoietic stem cells. J Biol Chem (2013) 0.83
Convergence of the thyroid hormone and gut-enriched Krüppel-like factor pathways in the context of enterocyte differentiation. J Gastrointest Surg (2003) 0.83
Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Am J Physiol Renal Physiol (2014) 0.82
CDK1 regulates mediator of DNA damage checkpoint 1 during mitotic DNA damage. Cancer Res (2012) 0.82
Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. Future Oncol (2009) 0.82
Quantitative endoscopy in the chemoprevention of Barrett's Esophagus Trial. Dis Esophagus (2008) 0.82
An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer. Curr Colorectal Cancer Rep (2011) 0.82
Expression profiling and pathway analysis of Krüppel-like factor 4 in mouse embryonic fibroblasts. Am J Cancer Res (2011) 0.82
Colon cancer: an update and future directions. Gastroenterology (2010) 0.82
Activation of the human pregnancy-specific glycoprotein PSG-5 promoter by KLF4 and Sp1. Biochem Biophys Res Commun (2006) 0.81
Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology (2005) 0.81
APC as a checkpoint gene: the beginning or the end? Gastroenterology (2002) 0.81
Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways. Cancer Lett (2002) 0.81
Chemoprevention of familial adenomatous polyposis by bromo-noscapine (EM011) in the Apc(Min/+) mouse model. Int J Cancer (2012) 0.79
High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer. Future Oncol (2012) 0.78
Prostaglandin E2 and Krüppel-like transcription factors synergistically induce the expression of decay-accelerating factor in intestinal epithelial cells. Immunology (2008) 0.77
Reinvesting in US biomedical research--the time is now. Gastroenterology (2009) 0.75
The future of physician-scientists-demise or opportunity? Gastroenterology (2006) 0.75
Our new president-Anil K. Rustgi, MD. Gastroenterology (2013) 0.75
Recent changes in relationships between medical school physicians and industry. Gastroenterology (2010) 0.75